Follow
Delvys Rodríguez-Abreu
Delvys Rodríguez-Abreu
Medical Oncologist at Hospital Universitario Insular de Gran Canaria/ Profesor asociado ULPGC
Verified email at gobiernodecanarias.org - Homepage
Title
Cited by
Cited by
Year
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer
M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
New England Journal of Medicine 375 (19), 1823-1833, 2016
96422016
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
60172012
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ...
New England journal of medicine 378 (22), 2078-2092, 2018
58132018
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...
New England Journal of Medicine 378 (24), 2288-2301, 2018
34242018
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
25292017
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
M Reck, D Rodríguez–Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
Journal of Clinical Oncology 37 (7), 537-546, 2019
14302019
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer
S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ...
Journal of clinical oncology 38 (14), 1505-1517, 2020
9372020
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in …
M Reck, TSK Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ...
The Lancet Respiratory Medicine 7 (5), 387-401, 2019
8722019
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
Journal of Clinical Oncology 39 (21), 2339-2349, 2021
6772021
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
6392020
Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
Lancet Oncol 13 (3), 239-246, 2012
6002012
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study
CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ...
Journal of Clinical Oncology 38 (21), 2369-2379, 2020
5142020
Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial
R Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, ...
Journal of Thoracic Oncology 15 (8), 1351-1360, 2020
4752020
Epidemiology of hematological malignancies
D Rodriguez-Abreu, A Bordoni, E Zucca
Annals of oncology 18, i3-i8, 2007
3772007
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ...
Annals of Oncology 32 (7), 881-895, 2021
3482021
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open …
JR Brahmer, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
The Lancet Oncology 18 (12), 1600-1609, 2017
3472017
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC
MA Socinski, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...
Journal of Thoracic Oncology 16 (11), 1909-1924, 2021
2992021
Perioperative pembrolizumab for early-stage non–small-cell lung cancer
H Wakelee, M Liberman, T Kato, M Tsuboi, SH Lee, S Gao, KN Chen, ...
New England Journal of Medicine 389 (6), 491-503, 2023
2962023
Immune checkpoint inhibitors: review and management of endocrine adverse events
E González-Rodríguez, D Rodríguez-Abreu, ...
The oncologist 21 (7), 804-816, 2016
283*2016
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line …
D Rodriguez-Abreu, ML Johnson, MA Hussein, M Cobo, AJ Patel, ...
Journal of Clinical Oncology 38 (15_suppl), 9503-9503, 2020
2592020
The system can't perform the operation now. Try again later.
Articles 1–20